Medical release archive

Lokelma label update approved in EU for patients with hyperkalaemia on stable haemodialysis

Lokelma US label updated to include dosing guidance for the treatment of hyperkalaemia in patients with end-stage renal disease on haemodialysis

Three clinical trials announced for Fasenra in eosinophil-driven skin diseases

Consistent effects of Farxiga in heart failure patients with reduced ejection fraction shown in new analyses from landmark Phase III DAPA-HF trial

Subgroup analysis of TWILIGHT trial patients with non-ST elevation acute coronary syndrome (NSTE-ACS) who underwent PCI showed Brilinta monotherapy reduced the risk of clinically relevant bleeding compared with dual antiplatelet therapy (DAPT)

New data from the Phase III DAPA-HF trial showed Farxiga (dapagliflozin) reduced the worsening of heart failure or cardiovascular death in HFrEF patients with and without chronic kidney disease

New analysis of Fasenra Phase III GALATHEA and TERRANOVA COPD trials identifies factors associated with exacerbation rate reductions

Brilinta monotherapy in high-bleeding risk patients who underwent PCI had reduced risk of clinically relevant bleeding than with dual antiplatelet therapy in the TWILIGHT trial

Forxiga reduced the risk of a composite of cardiovascular death or hospitalisation for heart failure in patients with type-2 diabetes, both with and without kidney disease

New data show Symbicort used as an anti-inflammatory reliever in mild-to-moderate asthma is more effective at preventing severe asthma attacks than maintenance budesonide plus terbutaline taken as-needed